PARTNER 3 and EVOLUT Confirm Benefits of TAVR Over Surgery in Low-Risk Patients – American College of Cardiology
Outcomes after transcatheter aortic valve replacement (TAVR) were superior or at least as good as those following surgical aortic valve replacement (SAVR) among patients with severe aortic stenosis at low surgical risk, according to results of the PARTNER 3 and EVOLUT trials presented at ACC.19 in New Orleans. Both studies were published simultaneously in the New…